{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1046"}]}],"title":"Primary (initiated in cycle1)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"401"}]}],"title":"Secondary (initiated in cycle2 or later)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"245"}]}],"title":"Delayed primary"},{"categories":[{"measurements":[{"groupId":"OG000","value":"156"}]}],"title":"True secondary"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1447"}],"units":"Participants"}],"description":"Objective 2: To describe EP2006 primary or secondary prophylaxis patterns for FN over up to 6 cycles of chemotherapy, with or without prior, concurrent, or later radiotherapy or surgery.","groups":[{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG000","title":"EP2006"}],"paramType":"NUMBER","populationDescription":"Delayed Primary: EP2006 initiated in cycle 2 or later with no CIN/FN in prior cycle.\n\nTrue secondary: EP2006 initiated in cycle 2 or later following CIN/FN in prior cycle.","reportingStatus":"POSTED","timeFrame":"All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days","title":"Type of EP2006 Prophylaxis","type":"PRIMARY","unitOfMeasure":"participants"}